ArticleInternational journal of nanomedicine2017
A nanoliposome-based photoactivable drug delivery system for enhanced cancer therapy and overcoming treatment resistance.
Article in International journal of nanomedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 39 citations in OpenAlex.
- PEGylated Nanoliposomes Encapsulated with Anticancer Drugs for Breast and Prostate Cancer Therapy: An Update.Pharmaceutics · 2025Review
- Designing Dual-Responsive Drug Delivery Systems: The Role of Phase Change Materials and Metal-Organic Frameworks.Materials (Basel, Switzerland) · 2024Review
- How Shilajit-Based Nanocarriers Alter Classical Doxorubicin Delivery to Breast Cancer Cells (MCF-7 and ZR-75-1).ACS medicinal chemistry letters · 2024Article
- Conjugated Nanoparticles for Solid Tumor Theranostics: Unraveling the Interplay of Known and Unknown Factors.ACS omega · 2023Review
- Insights into Lipid-Based Delivery Nanosystems of Protein-Tyrosine Kinase Inhibitors for Cancer Therapy.Pharmaceutics · 2022Review
- Soft nano and microstructures for the photomodulation of cellular signaling and behavior.Advanced drug delivery reviews · 2022Review
- Lipid-based nanoparticles for photosensitive drug delivery systems.Journal of pharmaceutical investigation · 2022Review
- A nanoselenium-coating biomimetic cytomembrane nanoplatform for mitochondrial targeted chemotherapy- and chemodynamic therapy through manganese and doxorubicin codelivery.Journal of nanobiotechnology · 2021Article
- Towards Tumor Targeting via Invasive Assay UsingFrontiers in microbiology · 2021Article
- Photodynamic Therapy for the Treatment and Diagnosis ofFrontiers in chemistry · 2021Review
- Preparation, characterization and therapeutic properties of gum arabic-stabilized gallic acid nanoparticles.Scientific reports · 2020Article
- Review
- Nanoliposomes as a Therapeutic Tool for Alzheimer's Disease.Frontiers in synaptic neuroscience · 2020Review
- Anthracyclines as Topoisomerase II Poisons: From Early Studies to New Perspectives.International journal of molecular sciences · 2018Review
- Nanotechnology for Cancer Therapy Based on Chemotherapy.Molecules (Basel, Switzerland) · 2018Review
- Quercetin and doxorubicin co-delivery using mesoporous silica nanoparticles enhance the efficacy of gastric carcinoma chemotherapy.International journal of nanomedicine · 2018Article
- Chitosan-alginate BSA-gel-capsules for local chemotherapy against drug-resistant breast cancer.Drug design, development and therapy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, stimuli-responsive drug delivery systems (DDSs) with high spatial/temporal resolution bring many benefits to cancer treatment. However, cancer cells always develop ways to resist and evade treatment, ultimately limit the treatment efficacy of the DDSs. Here, we introduce photo-activated nanoliposomes (PNLs) that impart light-induced cytotoxicity and reversal of drug resistance in synchrony with a photoinitiated and rapid release of antitumor drug. The PNLs consist of a nanoliposome doped with a photosensitizer (hematoporphyrin monomethyl ether [HMME]) in the lipid bilayer and an antitumor drug doxorubicin (DOX) encapsulated inside. PNLs have several distinctive capabilities: 1) carrying high loadings of DOX and HMME and releasing the payloads in a photo-cleavage manner with high spatial/temporal resolution at the site of actions via photocatalysis; 2) reducing drug efflux in MCF-7/multidrug resistance cells via decreasing the level of P-glycoprotein induced by photodynamic therapy (PDT); 3) accumulating in tumor site taking advantage of the enhanced permeability and retention effect; and 4) combining effective chemotherapy and PDT to exert much enhanced anticancer effect and achieving significant tumor regression in a drug-resistant tumor model with little side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.